GPR17抗体;GPR17 Antibody—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human esophagus cancer tissue using P13487(GPR17 Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P13487(GPR17 Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

GPR17 (G protein-coupled receptor 17) is an orphan receptor belonging to the rhodopsin-like family of G protein-coupled receptors (GPCRs). Initially identified as a dual receptor for both uracil nucleotides and cysteinyl leukotrienes, its endogenous ligands and precise physiological roles remain under investigation. GPR17 is predominantly expressed in the central nervous system (CNS), particularly in oligodendrocytes and their precursor cells, where it plays a regulatory role in myelination and remyelination processes. Dysregulation of GPR17 has been implicated in neurodegenerative diseases, such as multiple sclerosis, and ischemic brain injury, making it a potential therapeutic target.

Antibodies targeting GPR17 are critical tools for studying its expression, localization, and function. These antibodies are typically developed against specific epitopes, such as extracellular or intracellular domains, and validated for applications like immunohistochemistry, Western blotting, and flow cytometry. Due to the receptor's structural similarity with other GPCRs, antibody specificity is a key challenge. Recent studies have utilized GPR17 antibodies to explore its role in oligodendrocyte differentiation and neuroinflammation. Additionally, they aid in characterizing receptor trafficking and signaling mechanisms. As research progresses, high-quality GPR17 antibodies remain essential for elucidating its pathophysiological relevance and advancing drug discovery efforts.